Prescription Pricing for the People Act of 2025

Hozzl · 2025-04-15T04:23:16Z

Explore the details of Senate Bill 527 Prescription Pricing for the People Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on undefined. Stay informed on legislative developments.

4/15/2025, 4:23 AM

Summary of Bill S 527

Bill 119 s 527, also known as the "Pharmaceutical Supply Chain Intermediaries Study Act," is a proposed piece of legislation that aims to address the role of intermediaries in the pharmaceutical supply chain. The bill specifically calls for the Federal Trade Commission (FTC) to conduct a comprehensive study on the impact and influence of intermediaries within the pharmaceutical industry.

The main objective of the study is to provide Congress with valuable insights and policy recommendations regarding the role of intermediaries in the pharmaceutical supply chain. This includes examining how intermediaries such as pharmacy benefit managers (PBMs) and wholesalers impact drug pricing, access to medications, and overall market competition.

The bill emphasizes the importance of transparency and accountability within the pharmaceutical supply chain, highlighting the need for a better understanding of how intermediaries operate and their potential effects on consumers, healthcare providers, and pharmaceutical manufacturers. Overall, Bill 119 s 527 seeks to inform Congress on potential policy changes that could improve the efficiency and fairness of the pharmaceutical supply chain, ultimately benefiting patients and promoting a more competitive and transparent marketplace for prescription medications.

Congressional Summary of S 527

Prescription Pricing for the People Act of 2025

This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.

The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.

The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.

Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 527

Bill S 527 is currently in the status of Bill Introduced since February 11, 2025. Bill S 527 was introduced during Congress 119 and was introduced to the Senate on February 11, 2025. Bill S 527's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 42. as of April 10, 2025

Bipartisan Support of Bill S 527

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 527

Primary Policy Focus

Alternate Title(s) of Bill S 527

A bill to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes.